Who we are
Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
At a glance
Our company by the numbers
50,129,284
Patients with neurodegenerative diseases
42
Employees living and working across the world
58%
Improvement in memory functions for clinical trial patients
2016
Year we were officially founded
Meet the team
You?
Zach Malchano
President
Brent Vaughan
Chief Executive Officer
Everett Crosland
Chief Commercial Officer
Mihály Hajós
Chief Scientific Officer
Tom Megerian
Chief Medical Officer
Divya Cohen
Vice President, Product
Sean Gregory
Vice President, Health Economics & Market Access
Celine Houser
Vice President, Clinical Operations
Kim Kwan
Vice President, Research & Development
Jennifer Newberger
Vice President, Regulatory & Compliance
Martin Williams
Vice President, Business Development
Kimberly Ha
Vice President, PR & Investor Relations
The Founders
Ed Boyden
Founder
Li-Huei Tsai
Founder
Recognized and proud
Latest news and updates
Stay up to date
Aug 3, 2022
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
May 2, 2022
Some health apps are able not just to diagnose diseases, but also to treat them
Apr 13, 2022
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
Mar 31, 2022